The eye-a window on the kidney

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3582-3584

  D'Souza, Yvonne B ^a   Short, Colin D ^b  

^a MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Dense deposit disease; Retinal abnormalities

Indexed keywords

AGING; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONJUNCTIVITIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MICROALBUMINURIA; OPHTHALMOSCOPY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EYE DISEASES; HUMANS; KIDNEY DISEASES;

EID: 71049119041     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp406     Document Type: Article

References (33)

1. Parving H, Hommel E, Mathiesen E et al. Prevalence of microalbu-minuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med Journal 1988; 296: 156-160
2. Matthews DR, Stratton IM, Aldington SJ et al.; UK Prospective Diabetes Study Group. Risk of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS. Arch Ophthalmol 2004; 122: 1631-1640
3. Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972; 56: 800-804
4. Nolan J. Wegener's granulomatosis and the ophthalmologist. J HongKong Med Asso 1991; 43: 137-139
5. Izzedine H, Bodaghi B, Launay-Vacher V et al. Eye and kidney: from clinical findings to genetic explanations. J Am Soc Nephrol 2003; 14: 516-529
6. Appel G, Terence Cook H, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392-1403
7. Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 1989; 73: 297-302 (Pubitemid 19117557)
8. Bressler NM, Silva JC, Bressler SB et al. Clinicopathologic correlation of drusen and retinal pigment abnormalities in age-related mac-ular degeneration. Retina 1994; 14: 130-142
9. Bird AC, Bressler NM, Bressler SB et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39: 367-374
10. McAvoy CE, Silvestri G. Retinal changes associated with type 2 glomerulonephritis. Eye 2005; 19: 985-989
11. Duvall-Young J, Short CD, Raines MF et al. Fundus findings in mesangiocapillary glomerulonephritis type II: clinical and fluores-cein findings. Br J Ophthalmol 1989; 73: 900-906 (Pubitemid 20004004)
12. Leys A, Vanrenterghem Y, Damme BV et al. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein an-giographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol 1991; 229: 406-410
13. Kim DD, Mieler WF, Wolf MD. Posterior segment changes in mem-branoproliferative glomerulonephritis. Am J Ophthalmol 1992; 114: 593-599
14. Mullins RF, Aptisiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 2001; 15: 390-395
15. Raines MF, Duvall-Young J, Short CD. Fundus changes in mesangio-capillary glomerulonephritis type II: vitreous fluorophotometry. Br J Ophthalmol 1989; 73: 907-910 (Pubitemid 20004005)
16. O'Brien CO, Duvall-Young J, Brown M et al. Electrophysiology of type II mesangiocapillary glomerulonephritis with associated fundus abnormalities. Br J Ophthalmol 1993; 77: 778-780
17. D'souzaY,ShortCD, McLeodDet al. Long-term follow-up of drusen-like lesions in mesangiocapillary glomerulonephritis type II. Br J Ophthalmol 2008; 92: 950-953
18. Age-Related Eye Disease Study Group. A simplified severity scale for age-related macular degeneration: AREDS Report No 18. Arch Ophthalmol 2005 123 1570-1574
19. LeysA, VanrenterghemY, Van DammeBet al. Sequential observation of fundus changes in patients with long standing membranoprolifer-ative glomerulonephritis type II (MPGN type II). Eur J Ophthalmol 1991; 1: 17-22
20. D'souza YB, Jones CJ, Bonshek RE. Glycoproteins of drusen and drusen-like lesions. J Mol Histol 2008; 39: 77-86
21. Leathem AJC, Atkins NJ. Lectin binding to paraffin sections. In: Bullock GR, Petrusz P. (eds). "Techniques in Immunocytochemistry". Vol 2. London: Academic Press, 1983, 39-70
22. D'souza YB, Jones CJ, Short CD et al. Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II. Kidney Int 2009; 75: 824-827
23. Goodship THJ. Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II and AMD. Kidney Int 2006; 70: 12-13
24. Sivaprasad S, Chong NV. The complement system and age-related macular degeneration. Eye 2006; 20: 867-872
25. Baird PN, Islam FMA, Richardson AJ et al. Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest Ophthalmol Vis Sci 2006; 47: 4194-4198
26. Magnusson KP, Duan S, Sigurdsson H et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3: e5
27. Zipfel PF, Heinen S, Jozsi M et al. Defective alternate pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97-106
28. Crabb JW, Miyagi M, Gu X et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 2002; 99: 14682-14687 (Pubitemid 35334544)
29. Nevins TE. Lectin binding in membranoproliferative glomeru-lonephritis. Evidence for N-acetylglucosamine in dense intramem-branous deposits. Am J Pathol 1985; 118: 325-330
30. Han KH, Kang YS, Han SY et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120
31. Piecha G, Koleganova N, Gross ML et al. Regression of glomeru-losclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol 2008; 295: F137-F144
32. Mokwe E, Ohmit SE, Nasser SA et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the quinapril Titration Interval Management Evaluation trial. Hypertension 2004; 43: 1202-1207
33. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153-158